Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621244 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT00621244 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 175 participants.
The verdict
NCT00621244, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2003-03-01 |
| Est. Completion | 2009-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621244
The ClinicalTrials.gov registry entry for NCT00621244 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT00621244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621244 about?
NCT00621244 is a clinical study titled "A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies". This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
What is the current status of trial NCT00621244?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2003-03-01. Estimated completion is 2009-12-03.
What interventions are being tested in trial NCT00621244?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00621244?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.